相关临床试验
33
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1870
已完成
25
75.8%
招募中
7
21.2%
终止
1
3.0%
暂无批准数据
- A large-scale comparative analysis published in Nature Communications reveals that sperm conjugation—coordinated group behavior—is widespread across arthropods, challenging the long-held view of fertilization as purely competitive. - Researchers from Syracuse University, University of Siena, and University of Szeged found that sperm-associated material (SAM) plays a key role in binding sperm together, with the ancestor of all insects possessing conjugated sperm. - The findings open potential applications in human fertility research and pest control, including targeting SAM to disrupt reproduction in invasive species like the spotted lanternfly. - The study highlights that evolution has repeatedly gained and lost sperm cooperation across 600 million years, underscoring cooperation's critical role alongside competition in reproductive success.
- SureNano Science Ltd. has completed the acquisition of GlucaPharm Inc., gaining access to GEP44, a novel patented peptide developed at Syracuse University that targets obesity and metabolic disease with reduced gastrointestinal side effects compared to first-generation GLP-1 drugs. - GEP44 has demonstrated significant weight reduction and blood glucose normalization in preclinical studies without the nausea and gastrointestinal side effects commonly associated with current market leaders like Ozempic and Mounjaro. - The company plans to advance GEP44 through an IND-enabling FDA study followed by Phase I clinical trials in Australia, with key development milestones anticipated over the next six to nine months. - GlucaPharm's platform focuses on potential non-injectable delivery methods including oral, sublingual, or nasal administration, which could materially expand patient adoption and market penetration.
- SureNano Science Ltd. has entered into a non-binding letter of intent with GlucaPharm Inc. to potentially acquire the company and its exclusive rights to Syracuse University's GEP-44 GLP-1 compound technology. - GEP-44 is a novel triple antagonist compound designed for needle-free administration with superior tolerability compared to existing GLP-1 drugs like Ozempic, targeting reduced nausea and gastrointestinal side effects. - The proposed share exchange transaction would give GlucaPharm shareholders under 20% ownership of SureNano following completion of due diligence and regulatory approvals. - GEP-44 has demonstrated strong preclinical results and holds patent protection, positioning it as a potential breakthrough treatment for obesity and diabetes with improved patient experience.
- Researchers have developed two new peptide compounds, GEP44 and KCEM1, that target weight loss with potentially fewer gastrointestinal side effects than current GLP-1 drugs. - These compounds partner with PYY receptors, aiming to trigger significant weight loss without the nausea and vomiting often associated with GLP-1 receptor targeting medications. - A company co-owned by Syracuse University and the University of Pennsylvania is working to commercialize the compounds, with human trials anticipated within the next year. - Experts emphasize the need for a multidisciplinary approach to weight loss, including lifestyle and nutritional interventions, to address high discontinuation rates across weight loss treatments.
